Introduction:

Non-Insulin Therapies for Diabetes   Market was valued at US$ 72.5 Billion in 2024 and is projected to grow at a CAGR of 7.20% to reach US$ 145.1 Billion by 2034.

Non-insulin therapies are typically used in the treatment for type 2 diabetes patients, where patient’s body unable to produce sufficient insulin or body is incapable to use the insulin it produces. Non-insulin therapies have a different mechanism of action to maintain optimal glycemic control and to reduce blood glucose level. For instance, Sulfonylureas increase the insulin release from pancreatic cells and some agent like alpha-glucosidase inhibitors slow down the digestion of starch in the small intestine. 

As of now, rising global incidence and prevalence of diabetes is anticipated to boost the global non-insulin therapies for diabetes market during the forecast period. For instance, according to the International Diabetes Federation’s (IDF), the global prevalence of diabetic accounted for around 425 million, among of 400 million people were suffering from type 2 disease in 2017. Thus, this data represents a high prevalence rate of diabetes across the world, which eventually demand proper treatment management. Therefore, it is expected to propel the global non-insulin therapies for diabetic market within the forecast period. 

The world’s economic burden of diabetes is huge and is projected to rise during the forecast period. As per the American Diabetes Association, the total budget of diagnosed diabetes has increased up to US$ 327 billion in 2017 from around US$ 245 billion in 2012. Henceforth, the global market for non-insulin therapies for diabetes is anticipated to fuel the growth over the forecast period. 

However, the high cost of the novel class of drugs compared to conventional drugs may hamper the market growth over the forecast period.

Non-insulin therapies for diabetes market is categorized on the basis of drug class, route of administration, distribution channel, and region.

The drug class segment includes Alpha-Glucosidase Inhibitors, Biguanides, and Sulfonylureas Thiazolidinedione’s, DPP-4 Inhibitors, GLP-1 Analogs, and Sodium-glucose co-transporter-2 (SGLT2) inhibitors.

Further, the non-insulin therapies for diabetes market are segmented by route of administration, which includes oral and injectable.

• On the basis of the distribution channel, the non-insulin therapies for diabetes market is divided into retail pharmacy, hospital pharmacy, and online pharmacy.
• On the basis of region, the target market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East and Africa.  North America is projected to be the fastest growing region owing to the huge expenditure on diabetes treatment.

The key players operating in the non-insulin therapies for diabetes include AstraZeneca, Bristol-Myers Squibb, BoehringerIngelheim GmbH, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Merck and Company, Janssen Pharmaceuticals, Novartis AG, Sanofi Aventis, Novo Nordisk, Pfizer and Takeda Pharmaceuticals.

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
3. Market Preview
   • Executive Summary
   • Key Findings—Global Outlook for medical carts Strategies
     • Key Questions this Study will Answer
     • Market Snippet, By Drug Class
     • Market Snippet, By Route of Administration
     • Market Snippet, By Distribution Channel
     • Market Snippet, By Region
   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restrains
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis

Market Segmentation, By Drug Class, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Alpha-Glucosidase Inhibitors
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Biguanides
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Sulfonylureas Thiazolidinedione’s
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• DPP-4 Inhibitors
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• GLP-1 Analogs
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Sodium-glucose co-transporter-2(SGLT2)inhibitors
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Route of Administration, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Injectable
• Overview
• Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Non-Market Segmentation, By Distribution Channel, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Retail Pharmacy
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Hospital Pharmacy
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Online Pharmacy
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Global Market, By Region, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • U.S.
    • Canada
• Europe
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • UK
    • France
    • Germany
    • Russia
    • Italy
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Latin America
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years

• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East

1. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
2. Company Profiles 

• AsteaZenca
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Bristol-Myers Squibb
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Boehringerlngelheim GmbH
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Eli Lilly
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• F.Hoffmann-La Roche LTD.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• GlaxoSmithKline
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Merck and Company
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Janssen Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Novartis AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Sanofi Aventis
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

The Last Word

• Future Impact
• About Us
• Contact